ArticleJournal of biomedicine & biotechnology2010
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
Article in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.The American journal of tropical medicine and hygiene · 2018Pooled it
- Combined analysis of secreted proteins and glycosylation identifies prognostic features in cholangiocarcinoma.Journal of cellular physiology · 2024Article
- Upregulated LAMA3 modulates proliferation, adhesion, migration and epithelial‑to‑mesenchymal transition of cholangiocarcinoma cells.Scientific reports · 2023Article
- Translational Proteomic Approach for Cholangiocarcinoma Biomarker Discovery, Validation, and Multiplex Assay Development: A Pilot Study.Molecules (Basel, Switzerland) · 2022Article
- Effect of Derris scandens extract on a human hepatocellular carcinoma cell line.Oncology letters · 2018Article
- Annexin A5 regulates hepatocarcinoma malignancy via CRKI/II-DOCK180-RAC1 integrin and MEK-ERK pathways.Cell death & disease · 2018Article
- GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.Oncology letters · 2018Article
- Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.Frontiers in genetics · 2018Review
- Comparative protein profiles of Butea superba tubers under seasonal changes.Molecular biology reports · 2016Article
- Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma.Journal of translational medicine · 2016Article
- Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach.PloS one · 2015Article
- Diagnostic and prognostic serum marker of cholangiocarcinoma (Review).Oncology letters · 2015Article
- Matrigel induces L-plastin expression and promotes L-plastin-dependent invasion in human cholangiocarcinoma cells.Oncology letters · 2014Article
- Chemopreventive and chemotherapeutic effect of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model.Oncotarget · 2014Article
- Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.Journal of hepato-biliary-pancreatic sciences · 2014Review
- Global secretome analysis identifies novel mediators of bone metastasis.Cell research · 2012Article
- Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma.Clinical biochemistry · 2012Article
- Proteomic profiling of follicular and papillary thyroid tumors.European journal of endocrinology · 2012Article
- Article
- Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC) occur with relatively high incidence in Thailand. The secretome, proteins secreted from cancer cells, are potentially useful as biomarkers of the diseases. Proteomic analysis was performed on the secreted proteins of cholangiocarcinoma (HuCCA-1) and hepatocellular carcinoma (HCC-S102, HepG2, SK-Hep-1, and Alexander) cell lines. The secretomes of the five cancer cell lines were analyzed by SDS-PAGE combined with LC/MS/MS. Sixty-eight proteins were found to be expressed only in HuCCA-1. Examples include neutrophil gelatinase-associated lipocalin (lipocalin 2), laminin 5 beta 3, cathepsin D precursor, desmoplakin, annexin IV variant, and annexin A5. Immunoblotting was used to confirm the presence of lipocalin 2 in conditioned media and cell lysate of 5 cell lines. The results showed that lipocalin 2 was a secreted protein which is expressed only in the conditioned media of the cholangiocarcinoma cell line. Study of lipocalin 2 expression in different types of cancer and normal tissues from cholangiocarcinoma patients showed that lipocalin 2 was expressed only in the cancer tissues. We suggest that lipocalin 2 may be a potential biomarker for cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.